SHOP APOTHEKE EUROPE N.V.: Securities prospectus approved
DGAP-News: Shop Apotheke Europe N.V. / Key word(s): IPO
- Not for release, publication or distribution in the United States, Canada, Australia or Japan. -
- Securities prospectus has been approved by the AFM today
- Offer period begins on 29 September and is expected to end on 11 October 2016
- First day of trading in the Prime Standard segment of the Frankfurt Stock Exchange is expected for 13 October 2016
Venlo/Cologne, 28 September 2016 - The Dutch Authority for the Financial Markets (AFM) today approved the securities prospectus of SHOP APOTHEKE EUROPE N.V., one of the leading online pharmacies in Continental Europe, and notified the approval to the German Federal Financial Supervisory Authority (BaFin). The shares of SHOP APOTHEKE EUROPE will be offered from tomorrow, Thursday, 29 September 2016 until presumably Tuesday, 11 October 2016, in a range between EUR 28 and EUR 35.
'The IPO of SHOP APOTHEKE EUROPE is a major step forward to drive our expansion plans after we strengthened our European set-up significantly with the recent acquisition of the online pharmacy Farmaline. We are now looking forward to further accelerating our growth plans in major Continental European markets as a public company. At the same time, we are focusing on profitable growth in our German core market,' said Michael Koehler, CEO of SHOP APOTHEKE EUROPE.
The offer period for the up to 3,571,428 new shares from a primary offering will begin on Thursday, 29 September 2016, and is expected to end on Tuesday, 11 October 2016 at noon for retail investors and 2:00 p.m. (CET) for institutional investors. The company plans to achieve gross primary proceeds of EUR 100 million from the issuance of new shares. Proceeds from the primary offering are mainly designated to finance SHOP APOTHEKE EUROPE's growth, support further market penetration in Continental Europe, invest in continued expansion and automation of logistics and infrastructure, as well as repay shareholder loans.
In addition to the issuance of new shares, an over-allotment option (greenshoe) of up to c. 15 percent will be provided by the current shareholders. This corresponds to up to 535,714 additional shares from the holdings of existing shareholders.
The price range for the offered shares is set at EUR 28 to EUR 35. First day of trading in the SHOP APOTHEKE shares in the Prime Standard segment of the Frankfurt Stock Exchange under the ISIN: NL0012044747 (WKN A2AR94) is expected for 13 October 2016.
The offering consists of a public offering in Germany as well as private placements in certain other jurisdictions outside of Germany. In the United States of America, the offer will solely be addressed to 'qualified institutional buyers' as defined in Rule 144A under the Securities Act.
Detailed information about the IPO can be found in the SHOP APOTHEKE EUROPE prospectus, which has been approved by the Dutch Authority for the Financial Markets (AFM) and notified to the German Federal Financial Supervisory Authority (BaFin). The securities prospectus is available on the Company website on www.shop-apotheke-europe.com in the 'IPO' section.
ABOUT SHOP APOTHEKE EUROPE
SHOP APOTHEKE EUROPE is one of Continental Europe's leading online pharmacies with a portfolio that focuses on OTC medication and pharmacy-related BPC products. The company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, TÜV-certified shop-apotheke.com is the market leader in terms of traffic, delivering a broad range of approximately 100,000 original products to about 1.5 million active customers quickly and at a good price. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.
SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE EUROPE also has an administration site for its sales and marketing units in Cologne (Germany).
Trade and public media: